BACKGROUND: While inadequate treatment intensification may contribute to sub-optimal CVD risk factor control in older patients with diabetes, the relationship between patient age and treatment intensification is largely unexplored.
INTRODUCTION
Control and treatment of cardiovascular disease (CVD) risk factors in diabetes, especially blood pressure (BP) and lipids, significantly reduces morbidity and mortality. [1] [2] [3] CVD risk factor control is of particular importance in older adults; studies have shown that treatment of high BP in particular resulted in a significant decrease in heart disease and mortality in older age groups. 4, 5 The effect of age on CVD risk factor control is variable. While older adults have better glycemic control 6 and LDL control 7 than younger patients, they have worse BP control. 8 One central reason that patients fail to achieve target CVD risk factor control is lack of timely treatment intensification, or the modification of drug therapy in response to elevated CVD risk factor levels, by the provider. 9, 10 There are many potential barriers to treatment intensification in older patients with diabetes, including decreased functional status, polypharmacy, shorter life expectancy and controversy regarding optimal risk factor control levels in older adults. 11, 12 However, little is known about whether age is independently associated with the likelihood of receiving treatment intensification in adults with diabetes. 13 The purpose of this study is to examine differences in CVD treatment intensification and risk factor control in older vs. younger patients with diabetes.
METHODS
We conducted this study in one of six centers of Treatment Intensification. We assessed treatment intensification for each CVD risk factor separately using KP prescription databases for the 3 months before and the 3 months following first measurement of above target levels (for SBP, we used the date of the second reading). We denoted that intensification occurred if there was (1) an increase in the number of drug classes being prescribed, (2) an increase in the daily dosage of at least one ongoing drug class or (3) a switch to a medication in a different drug class. For both medication adherence and treatment intensification in diabetes, we excluded patients using insulin at the time of target A1c assessment since we can neither assess treatment adherence nor treatment intensification of insulin through pharmacy records.
Multivariate Analyses. We used probit models to assess the marginal effect of patient age on control and treatment intensification for CVD risk factors. We a priori stratified age into four groups: <50 years (reference group), 50-64 years, 65 to 74 years and 75-85 years. All analyses were adjusted for patient gender, baseline laboratory or BP values (recorded at least 3 months prior to poor control event), number of comorbidities, race/ethnicity, preferred language, number of primary care visits in 2005, number of medication classes taken for a condition prior to baseline laboratory or BP value, Medicare status (yes/no), geo-coded education and geo-coded income as fixed effects. We performed geo-coding by linking data from the US Census 2000 on income and education at the block group level to each patient using their address in 2005; resulting education and income level for the block group was used for each patient. Models predicting treatment intensification also adjusted for good vs. poor patient adherence to medications. Treatment adherence was calculated with KP prescription databases 9 using continuous multiple interval measures of gaps in therapy (CMG). 14 We defined good adherence as cumulative days of refill gaps equal to or less than 20% for each condition. Models also adjusted for physician age, gender, race/ ethnicity, languages spoken, number of patients in a panel, number of diabetes patients in a panel and for patient clustering within physician using a random effect. For ease of presentation, we converted the resulting marginal effects into adjusted percentages of patients below target for each CVD risk factor and adjusted percentages of patients above target CVD risk factor levels who received treatment intensification for each of the three CVD risk factors. All analyses were performed using STATA version 10.
RESULTS
The characteristics of patients in the study sample by age group are presented in Table 1 . Risk factor control varied by age in both adjusted and unadjusted analyses (Table 2 ). This was most pronounced for glycemic control, with proportions in control increasing sharply with age (69% for age <50 vs. 91% for age 75-85). In contrast, proportions in control for SBP<140 mmHg decreased with age (78% for age <50 vs. 69% for age 75-85).
Among patients with poor SBP control, treatment intensification was slightly higher for patient ages 50-64 and ages 65-74 than for patients under age 50 (74.3% and 75.7% vs. 71%, respectively). In contrast, for patients with poor glycemic control, older age was associated with a slightly lower likelihood of treatment intensification (72.8% for those aged 65-74 vs. 76.5% for the reference age group). There was no difference in treatment intensification for poorly controlled lipids by age; however, overall rates of intensification for lipids were lower (<50% for all age groups) than those for A1c and SBP. The relationships between treatment intensification and age were not affected by whether patient medication adherence was controlled for in the model or whether lower thresholds for BP control (SBP<130) were examined (data not shown).
DISCUSSION
Our study demonstrates that treatment intensification was slightly higher among older compared to younger diabetic adults with elevated SBP. Our findings contrast with earlier studies showing lower intensification of antihypertensive regimens for older patients. 13, 15 These findings suggest that efforts focused on increasing awareness of the importance of BP control for older patients may be succeeding. In contrast, a lower percent of older adults with poor glycemic control received treatment intensification, and intensification decreased with increasing age. Because of the lack of strong evidence that tight glycemic control is beneficial in older adults, providers may be less likely to intensify regimens. 16 There was no relationship between patient age and treatment intensification for hyperlipidemia, in contrast to previous studies that demonstrated that older adults were intensified less than patients in other age groups. 17, 18 Treatment intensification rates for hyperlipidemia were much lower than those for hypertension and hyperglycemia. Future work should identify barriers to appropriate treatment intensification for hyperlipidemia that might improve appropriate lipid control among older diabetes patients. Despite greater level of treatment intensification for BP in older adults, BP control in this group is still somewhat poorer than for younger patients. These findings are consistent with previous studies. 7, 19, 20 It is also possible that there are factors contributing to poor BP control in the elderly outside of pharmacological treatment. Further studies should explore these relationships and monitor trends in BP levels in diabetes patients across ages over time. It is interesting to note that despite lower treatment intensification for hyperglycemia, older adults had better control of their A1c. Therefore, it is likely that factors other than treatment intensification contribute to improved control for hyperglycemia among older adults. We found that levels of control for LDL-c were lower than for SBP and A1c among older adults. Given the importance of lipid control in order adults, further work should explore the barriers to lipid control in older patients with diabetes.
Limitations
There are a number of limitations in this study that should be noted. Results were based on administrative data, and we were unable to evaluate patient and provider perspectives on the need for treatment intensification. Patients and providers were from a single, large, integrated health-care delivery system; it is possible that rates of risk factor control and treatment intensification may be different in other settings. Finally, we were unable to assess treatment intensification for hyperglycemia in patients already on insulin, which may underestimate our treatment intensification rates in this group.
CONCLUSIONS
Our study demonstrated slightly higher treatment intensification for poor SBP control among older diabetic adults as compared to younger patients. However, control of BP, A1c and LDL cholesterol control varied somewhat by age. While control of SBP in older patients has improved compared to previous studies, older patients still have lower rates of SBP control than their younger counterparts. Further studies that incorporate provider perspectives are necessary to understand provider treatment intensification patterns for older adults and to explore reasons why BP control is persistently lower in older patients with diabetes. CVD = Cardiovascular, CI = confidence interval, SBP = systolic blood pressure, A1c = glycated hemoglobin All analyses adjusted for patient gender, baseline laboratory values, number of comorbidities, race/ethnicity, preferred language, number of primary care visits in 2005, number of medication classes taken for a condition, Medicare status (yes/no), geo-coded education and income as random effects and provider as fixed effects. Reference was age <50 years †Among those not well controlled Treatment intensification was defined as any one of the following three occurrences: (1) an increase in the number of drug classes being prescribed, (2) an increase in the daily dosage of at least one ongoing drug class or (3) a switch to a medication in a different drug class † †Increase in hypoglycemic therapy was only determined for individuals not taking insulin at baseline
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